The Clinical Case

Metabolic health is psychiatric health

Metabolic dysfunction contributes to mood dysregulation, cognitive impairment, and treatment resistance. Psychiatric illness — and psychiatric medications — frequently drives metabolic compromise in return.

Antidepressants, mood stabilizers, and antipsychotics are among the most metabolically burdensome medication classes in medicine. Addressing metabolic health within the psychiatric relationship produces superior outcomes to siloed treatment.

GLP-1 receptor agonists reduce neuroinflammation, improve insulin sensitivity, modulate reward circuits, and reduce compulsive behavior patterns. These are psychiatric mechanisms — not incidental side effects of weight loss.

"Every metabolic intervention at Welmivia is justified by a documented psychiatric indication. The patient's chart reflects how metabolic status contributes to psychiatric presentation — before any agent is initiated."

Dr. Sonia Mia Diaz, M.D. — Clinical Standard

Precision Psychiatry Integration

GLP-1 & Metabolic Management for Psychiatric Health

Q: How is Welmivia's GLP-1 management different from a telehealth weight-loss clinic?

A qualifying psychiatric diagnosis is required — Welmivia does not prescribe GLP-1 therapy based on weight goals alone. Monitoring is integrated into psychiatric follow-up visits. The clinical framing is metabolic psychiatric care — addressing how metabolic status affects mood, cognition, and treatment response — not cosmetic or elective weight management.

The connection between metabolic dysfunction and psychiatric illness is bidirectional and well-established. At Welmivia, GLP-1 therapy isn't a weight-loss program — it's a metabolic psychiatric intervention, justified by your diagnosis and monitored within your ongoing care.

Schedule a Fit Call

This is not a weight-loss clinic

Psychiatric diagnosis is a prerequisite — not weight alone. Every prescription is justified by a documented clinical indication.

Integrated, not parallel

Metabolic monitoring lives inside your psychiatric follow-up visits. No separate clinic, no siloed care.

Compounded with purpose

All formulations include B6 (P5P) and B12 (methylcobalamin) — required cofactors for serotonin and dopamine synthesis.

Membership-based access

Ongoing GLP-1 management is available to Core and Signature members. Medications sourced directly from vetted pharmacies.

Patient Selection

Qualifying psychiatric indications

You do not need a BMI of 30+ to qualify. Psychiatric medication-induced weight gain of 5–7% or more, metabolic lab abnormalities, or documented distress related to body composition — in the presence of a qualifying diagnosis — constitutes sufficient clinical justification.

F32–F33

Major Depressive Disorder

Antidepressant-related weight gain (SSRIs, SNRIs, mirtazapine, TCAs); neuroinflammatory overlap; metabolic syndrome comorbidity.

F31

Bipolar Disorder

Mood stabilizer and antipsychotic-associated metabolic syndrome; lithium/valproate weight gain; insulin resistance.

F41.1

Generalized Anxiety Disorder

HPA axis dysregulation; cortisol-driven visceral adiposity; emotional eating patterns.

F43.10

PTSD

HPA axis dysregulation; trauma-related appetite dysregulation; antidepressant weight gain; body image distress.

F90

ADHD

Impulsive eating; reward dysregulation; stimulant appetite suppression followed by rebound hyperphagia.

F50.81

Binge Eating Disorder

GLP-1 mechanism directly addresses reward-driven overeating; reduces binge frequency and urge intensity.

The Welmivia Formulary

Agents selected for psychiatric precision

All prescriptions are compounded 503A formulations through Preston's Pharmacy and Empower Pharmacy. Medications are sourced and paid by the patient directly.

Semaglutide

Weekly SQ — GLP-1 Receptor Agonist

Preferred first-line agent. Once-weekly dosing with the broadest evidence base. Strong GLP-1 receptor selectivity. Titrated from 0.25 mg to maintenance at 2.4 mg over 16+ weeks.

Tirzepatide

Weekly SQ — Dual GLP-1/GIP Agonist

Superior metabolic outcomes versus semaglutide. GIP co-agonism adds incremental benefit. Preferred for treatment-resistant metabolic depression or patients requiring greater metabolic effect.

Liraglutide

Daily SQ — Alternative Dosing Profile

Once-daily dosing. Side effects concentrate in a single daily window — preferred when weekly agents cause prolonged nausea. Formulated with B6/B12 per Welmivia standard.

The Process

From evaluation to ongoing care

1

Precision Psychiatric Evaluation

$450 initial evaluation establishes your diagnosis, reviews medication history, and delivers a Blueprint including whether GLP-1 management is indicated.

2

Baseline Labs & Screening

Comprehensive metabolic panel, HbA1c, insulin, lipids, B12, B6, and thyroid labs. Patient pays LabCorp or Quest directly.

3

Prescription & Pharmacy

Compounded GLP-1 with B6/B12 co-formulation sent to Preston's Pharmacy or Empower Pharmacy. You source the medication directly.

4

Membership-Based Monitoring

Titration, metabolic review, and lab oversight within your monthly membership visits. Core and Signature members have ongoing access.

Ongoing GLP-1 management requires active membership

Core ($325/mo) and Signature ($525/mo) membership includes GLP-1/metabolic management access within scheduled follow-up visits.

View Membership

Common Questions

What patients ask us

Do I need to have obesity to qualify for GLP-1 therapy at Welmivia?

No. Weight is not the primary qualifying criterion. Psychiatric medication-induced weight gain of 5–7% or more, documented metabolic abnormalities, body image distress linked to weight, or a psychiatric diagnosis with established metabolic relevance all constitute sufficient clinical justification. Dr. Diaz makes this determination based on your individual presentation, not a BMI cutoff.

Why does Welmivia prescribe compounded GLP-1s?

Welmivia often recommends compounded GLP-1 formulations because they allow for the inclusion of B12 (methylcobalamin), which can support energy and reduce the need for separate injections. Compounding also allows for more precise dose customization and titration. Commercially available brand-name GLP-1 medications and separate B12 supplementation can be prescribed upon request.

How is this different from a telehealth weight-loss clinic?

A qualifying psychiatric diagnosis is required — we don't prescribe GLP-1 therapy based on weight goals alone. Monitoring is integrated into your psychiatric follow-up visits. The clinical framing is metabolic psychiatric care — addressing how metabolic status affects mood, cognition, and treatment response — not cosmetic or elective weight management.

What happens if I need to stop GLP-1 therapy?

Discontinuation at Welmivia is a structured clinical event. Weight regain after cessation can directly precipitate psychiatric decompensation in patients whose treatment included body image distress or mood-weight coupling. Dr. Diaz uses a formal discontinuation assessment, a bridge plan, and a scheduled follow-up — there is no unmonitored exit from GLP-1 therapy.

Ready to begin integrated metabolic care?

New patients start with a Precision Psychiatric Evaluation. This visit reviews psychiatric history, metabolic context, current medications, treatment goals, and whether GLP-1-based support fits appropriately within a broader care plan.

GLP-1 and metabolic management are monitored adjuncts within Welmivia care, with medications billed separately and ongoing access tied to active membership when indicated.

Ready to schedule?

Start with a Precision Psychiatric Evaluation

Interested in integrated GLP-1, hormone, peptide, hair, or sexual wellness support? New patients begin with a comprehensive Precision Psychiatric Evaluation to clarify goals, review history, and determine whether these services fit appropriately within your care plan.

Initial evaluation: $450

Virginia & Florida residents only

Direct-pay · Superbills on request

Ongoing monitored adjunctive therapies, including GLP-1 and peptide-based metabolic management, are addressed within the Welmivia care framework after evaluation when clinically appropriate.

Virginia & Florida Telehealth

Ready to address the metabolic dimension of your psychiatric care?

Schedule a free 10-minute fit call. All care is direct-pay with superbills available for out-of-network reimbursement.

Schedule Your Fit Call

Welmivia Medical, PLLC · Dr. Sonia Mia Diaz, M.D. · Virginia & Florida Telehealth · Direct-Pay · Superbills Available
This page is for informational purposes only and does not constitute medical advice. GLP-1 therapy requires a clinical evaluation and active membership.

Existing patients: log into the patient portal for clinical messages.

Message received

Thank you for reaching out. We'll be in touch within one business day.